Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data

Research output: Contribution to journalArticle

178 Citations (Scopus)
Original languageEnglish
Pages (from-to)1574-82
JournalAmerican Journal of Gastroenterology
DOIs
Publication statusPublished - Jul 2010

Cite this